Brokerages Expect Citius Pharmaceuticals Inc (NASDAQ:CTXR) to Announce ($0.12) Earnings Per Share

Citius Pharmaceuticals Inc (NASDAQ:CTXR) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1 year consensus price objective of $7.00 for the company and are expecting that the company will post ($0.12) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Citius Pharmaceuticals an industry rank of 54 out of 255 based on the ratings given to its competitors.

A number of equities analysts recently commented on the stock. Dawson James assumed coverage on shares of Citius Pharmaceuticals in a research note on Friday, September 6th. They issued a “buy” rating and a $7.00 price objective for the company. Zacks Investment Research lowered shares of Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, October 14th.

Citius Pharmaceuticals stock traded down $0.01 during mid-day trading on Monday, hitting $0.57. The company’s stock had a trading volume of 48,340 shares, compared to its average volume of 258,166. The stock has a market capitalization of $12.81 million, a P/E ratio of -0.48 and a beta of 0.62. Citius Pharmaceuticals has a twelve month low of $0.42 and a twelve month high of $1.79. The stock’s fifty day moving average price is $0.85 and its two-hundred day moving average price is $1.06.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.14). As a group, analysts anticipate that Citius Pharmaceuticals will post -0.61 earnings per share for the current year.

In related news, major shareholder Leonard L. Mazur bought 2,234,700 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was bought at an average price of $0.90 per share, with a total value of $2,011,230.00. Also, CEO Myron Z. Holubiak bought 5,000 shares of the firm’s stock in a transaction on Wednesday, September 25th. The shares were bought at an average cost of $6.02 per share, with a total value of $30,100.00. Insiders have acquired a total of 2,798,297 shares of company stock valued at $2,544,067 in the last three months. Company insiders own 58.52% of the company’s stock.

A hedge fund recently raised its stake in Citius Pharmaceuticals stock. Vanguard Group Inc. raised its stake in shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 308.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 453,156 shares of the company’s stock after buying an additional 342,180 shares during the period. Vanguard Group Inc. owned about 2.05% of Citius Pharmaceuticals worth $444,000 as of its most recent SEC filing. Institutional investors own 2.83% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

Further Reading: What is a Futures Contract?

Get a free copy of the Zacks research report on Citius Pharmaceuticals (CTXR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.